Recruiting
Phase 2

A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

Sponsor:

Genentech, Inc.

Code:

NCT04302025

Conditions

Non-small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Alectinib

Entrectinib

Vemurafenib (Enrollment closed)

Cobimetinib (Enrollment closed)

Pralsetinib (Enrollment closed)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information